📰 Full Story
Aurora Cannabis Inc. reported fiscal third-quarter 2026 results on Feb. 4, 2026 for the period ended Dec. 31, 2025, highlighting a strategic pivot to higher-margin global medical cannabis.
Total net revenue rose 7% year-over-year to C$94.2 million, with global medical revenue setting a record at C$76.2 million (up 12%). Consolidated adjusted gross margin improved 100 basis points to 62%; medical margins were 69%. Adjusted EBITDA was C$18.5 million and adjusted net income C$7.2 million.
The company generated positive free cash flow of C$15.5 million and held C$154.4 million in cash and short-term investments, reporting no cannabis-business debt.
Management said it will exit select lower-margin Canadian consumer markets, sell its controlling stake in plant-propagation business Bevo (to be treated as discontinued operations), and expects some one-time Q4 costs tied to those actions.
Aurora also filed a prospectus supplement to establish an at-the-market (ATM) equity program to issue up to US$100 million of common shares to fund cultivation capacity, GMP expansion and potential M&A. Near-term headwinds include a 48% drop in consumer cannabis revenue and a sharp decline in plant propagation margins to 16% (including inventory write-offs).
🔗 Based On
GuruFocus New ArticleAurora Cannabis Inc (ACB) (Q3 2026) Earnings Call Highlights: Strategic Shifts and Global ...
GuruFocus New ArticleQ3 2026 Aurora Cannabis Inc Earnings Call Transcript






















💬 Commentary